EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosa

Miquel Àngel Sastre-Femenia, Maria Antonia Gomis-Font, Antonio Oliver iD

Antimicrobial Agents and Chemotherapy · 02.04.2025 · 69 (4)

DOI: 10.1128/aac.01942-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.04.2025. Verfasst von Miquel Àngel Sastre-Femenia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Hospital Universitari Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), CIBERINFEC, Palma, Spain. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Anti-Bacterial Agents, beta-Lactams. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A growing number of novel antipseudomonal β-lactams have been introduced in recent years, but the emergence of resistance is still a major concern in the treatment of Pseudomonas aeruginosa infections. Here, we compared the mutant prevention concentrations (MPCs) and the nature of first-step resistant mutants to classical and novel β-lactams in P. aeruginosa . MPCs were determined in duplicate experiments for ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, aztreonam, aztreonam/avibactam, and cefiderocol in PAO1, PAOMS (Δ mutS ), and three extensively drug-resistant (XDR) clinical strains belonging to high-risk clones ST111, ST175, and ST235. Four mutants per strain and antibiotic, obtained from the highest concentration showing growth, were characterized through the determination of the susceptibility profiles and whole genome sequencing. Imipenem/relebactam presented the lowest MPC values, followed by ceftolozane/tazobactam. Overall, the MICs of the mutants were consistent with the antibiotic selection concentration, except for cefiderocol, which were much lower. MPCs were lower for ceftazidime/avibactam and imipenem/relebactam than those of the corresponding β-lactam alone. In contrast, MPCs of meropenem ± vaborbactam and aztreonam ± avibactam were identical in most strains. Ceftolozane/tazobactam and ceftazidime/avibactam derivatives presented mutations in ampC , galU , cpxRS, and/or in bla OXA-2 when present in the parent strain (ST235). Cefiderocol mutants were mainly defective in iron-uptake systems, particularly PiuA/DC. All carbapenems had oprD as the first-step mechanism. Imipenem/relebactam, meropenem ± vaborbactam, and aztreonam ± avibactam selected mutations frequently included efflux pumps and regulators. Imipenem ± relebactam also selected aroB mutations. This work first describes the MPCs and first-step resistance mechanisms for classical and novel β-lactams in P. aeruginosa . The identified shared and differential resistance development patterns between the available classical and novel β-lactams should be helpful to guide treatment strategies for XDR P. aeruginosa infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAnti-Bacterial Agentsbeta-LactamsMicrobial Sensitivity TestsAzabicyclo CompoundsCeftazidimeImipenemCephalosporinsTazobactamMeropenemAztreonambeta-LactamasesMutationDrug Resistance, Multiple, BacterialBacterial ProteinsDrug CombinationsHumansCefiderocolPseudomonas InfectionsBoronic AcidsHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

Pseudomonas aeruginosabeta-lactamsgenomicsmutant prevention concentrationresistance

Substanzen

Anti-Bacterial Agentsbeta-LactamsAzabicyclo CompoundsCeftazidimeImipenemCephalosporinsTazobactamMeropenemAztreonambeta-Lactamases

Autor:innen und Institutionen

  • Department of Microbiology, Hospital Universitari Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), CIBERINFEC, Palma, Spain.

ORCID-Profile: Antonio Oliver

Förderung

  • Ministerio de Ciencia e Innovación

Zitieren

APA

Sastre-Femenia, M. À., Gomis-Font, M. A., & Oliver, A. (2025). Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 69(4). https://doi.org/10.1128/aac.01942-24

Vancouver

Sastre-Femenia MÀ, Gomis-Font MA, Oliver A. Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2025;69(4). doi:10.1128/aac.01942-24

BibTeX
@article{SastreFemenia2025,
  author = {Sastre-Femenia, Miquel Àngel and Gomis-Font, Maria Antonia and Oliver, Antonio},
  title = {Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosa},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {4},
  doi = {10.1128/aac.01942-24}
}
Kostenlos starten →